rapharad.com

What it is

RaphaRAD (rapharad.com) is a radiotherapy technology company founded in 2021 by experts in medical physics from South Korea. Its core team comes from top clinical institutions including the National Cancer Center of Korea, and the company focuses on developing innovative products covering the entire workflow of tumor radiotherapy. Its product portfolio falls into three major categories: precision treatment delivery, treatment quality verification, and patient protection. RaphaRAD currently has 6 products in its pipeline, and multiple mature products have already been commercialized.

Core Features & Pricing

The company's products are divided into three main segments:

1. Quality verification: This includes the BIM system, which completes brachytherapy source position and dwell time verification in just 100 seconds, and the LIM system, which cuts the full-process QA time for linear accelerators from 60 minutes to under 20 minutes, greatly reducing clinical labor costs.
2. Patient protection: The already commercialized Lens-OK reduces the radiation dose to the eye lens during radiotherapy to an extremely low level, without compromising CT imaging quality.
3. Innovative treatment: This segment includes Brad-FIT, an intensity-modulated brachytherapy system that enables precise dose control; Pro-MI, a proton microbeam therapy system that reduces damage to healthy tissue; and Gold-DOT, a tumor localization marker with lower dose interference. Most of these products are still in development.

No standardized pricing is publicly listed on the official website. All products are sold to B2B medical institutions, and you need to contact the team through the website to get a customized quote.

Pros & Cons, Suitable Use Cases, and Accessibility

Pros: All products are developed by frontline clinical experts, and accurately solve common pain points in radiotherapy scenarios including low QA efficiency and high healthy tissue damage. Its technology patent portfolio covers multiple major global healthcare markets, and the company leverages R&D resources from top-tier cancer centers.
Cons: Innovative treatment products are not yet fully commercialized, the company does not sell directly to individual consumers, the website only supports English, and there is no localized service information for the Chinese market.

The website is currently directly accessible from mainland China. It is a good reference and contact point for domestic radiotherapy centers and cancer hospitals looking to source new radiotherapy QA equipment or develop precision radiotherapy technology.